Schlatter J, Nguyen D, Zamy M, Kabiche S, Fontan J, Cisternino S
Eur Spine J. 2017; 28(1):21-30.
PMID: 29151132
DOI: 10.1007/s00586-017-5387-x.
Kim H, Choi B, Lim H, Min H, Oh J, Choi S
Mol Pain. 2017; 13:1744806917697006.
PMID: 28326946
PMC: 5407664.
DOI: 10.1177/1744806917697006.
Abu-Mugheisib M, Benecke R, Zettl U
Mult Scler Int. 2011; 2011:219049.
PMID: 22096630
PMC: 3196978.
DOI: 10.1155/2011/219049.
Nelson J
West J Med. 1977; 127(2):133-4.
PMID: 18748013
PMC: 1237729.
Nelson D, Landau W
J Neurol Neurosurg Psychiatry. 2001; 70(4):433-43.
PMID: 11254764
PMC: 1737322.
DOI: 10.1136/jnnp.70.4.433.
Pharmaceutical excipients. Adverse effects associated with 'inactive' ingredients in drug products (Part II).
Golightly L, Smolinske S, Bennett M, Sutherland 3rd E, Rumack B
Med Toxicol Adverse Drug Exp. 1988; 3(3):209-40.
PMID: 3041246
DOI: 10.1007/BF03259883.
Multiple sclerosis intra-blood-brain-barrier IgG synthesis: effect of pulse intravenous and intrathecal corticosteroids.
Baumhefner R, Tourtellotte W, Syndulko K, Staugaitis A, Shapshak P
Ital J Neurol Sci. 1989; 10(1):19-32.
PMID: 2925343
DOI: 10.1007/BF02333869.
Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study.
Heun R, Sliwka U, Ruttinger H, Schimrigk K
J Neurol. 1992; 239(1):31-5.
PMID: 1541966
DOI: 10.1007/BF00839208.
Sclerosing spinal pachymeningitis. A complication of intrathecal administration of Depo-Medrol for multiple sclerosis.
Bernat J, Sadowsky C, Vincent F, Nordgren R, Margolis G
J Neurol Neurosurg Psychiatry. 1976; 39(11):1124-8.
PMID: 1037000
PMC: 1083313.
DOI: 10.1136/jnnp.39.11.1124.
Modifications of the cerebrospinal fluid IgG concentrations in patients with multiple sclerosis treated with intrathecal steroids.
Massaro A
J Neurol. 1978; 219(4):221-6.
PMID: 84055
DOI: 10.1007/BF00312975.
